加拿大ART Advanced Research Technologies Inc. (ART) www.art.ca
ART Advanced Research Technologies Inc. (蒙特利尔，Montreal)是在医学及医药产业方面领先的光学分子成像技术研发公司。 宣布将用公司的SoftScan breast imaging system乳房成像系统，加入美国FDA的STED Pilot Program研究计划。
ART Advanced Research Technologies Inc. (ART) researches, designs, develops and markets optical imaging products for the medical and pharmaceutical industries. ART has developed several products that relate to medical imaging, medical diagnostics, medical research and drug discovery.

Optix is an in vivo optical molecular imaging device designed to monitor physiological changes in small animals during preclinical drug studies. Industry and academic leaders worldwide use Optix to bring new and better treatments to patients faster.

SoftScan is an optical breast imaging device designed to improve the diagnosis and treatment of breast cancer. Marketed under the name SoftScan, it uses ART’s unique molecular imaging technology to display and discriminate between normal and malignant tissue. ART has a global strategic alliance with GE Healthcare, a world leader in mammography and imaging, to commercialize SoftScan.

The Fenestra line of molecular imaging contrast products provide image enhancement for a wide range of preclinical MicroCT applications. For instance, it allows scientists to see greater detail in their imaging studies. It also has potential for other major imaging applications.

ART has been listed on the Toronto Stock Exchange since June 29, 2000, under the trading symbol ARA (TSX: ARA).

Members of ART's Management Team, Board of Directors and advisory boards are listed in the Investors' section.